Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

PMID:
25567330
2.

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration.

AIDS. 2012 Aug 24;26(13):1691-705.

3.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration.

Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28.

4.

[Aregenerative anemia and erythrocytes hemighosts: a case report].

Bibi-Triki T, Bélien V, Chapelon E, Sauvion S, Gaudelus J, Laurian Y, de Pontual L.

Ann Biol Clin (Paris). 2011 Jul-Aug;69(4):481-4. doi: 10.1684/abc.2011.0602. French.

PMID:
21896417
5.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

HIV-CAUSAL Collaboration, Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.

Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001.

6.

Protein S inherited qualitative deficiency: novel mutations and phenotypic influence.

Alhenc-Gelas M, Canonico M, Morange PE, Emmerich J; Geht Genetic Thrombophilia Group.

J Thromb Haemost. 2010 Dec;8(12):2718-26. doi: 10.1111/j.1538-7836.2010.04073.x.

PMID:
20880255
7.

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

HIV-CAUSAL Collaboration, Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA.

AIDS. 2010 Jan 2;24(1):123-37. doi: 10.1097/QAD.0b013e3283324283.

8.

Is rituximab effective in acquired von Willebrand syndrome?

Mazoyer E, Fain O, Dhote R, Laurian Y.

Br J Haematol. 2009 Mar;144(6):967-8. doi: 10.1111/j.1365-2141.2008.07538.x. Epub 2008 Dec 12. No abstract available.

PMID:
19120364
9.

[Peripheral and bone marrow plasmacytosis in dengue fever: report of a case].

Bibi-Triki T, Aras N, Braun T, Lautridou C, Boukari L, Morin AS, Maquarre E, Stirnemann J, Brichler S, Laurian Y, Fain O.

Rev Med Interne. 2009 Mar;30(3):274-6. doi: 10.1016/j.revmed.2008.05.012. Epub 2008 Jun 26. French.

PMID:
18584920
10.

Management of haemophilic arthropathy.

Bossard D, Carrillon Y, Stieltjes N, Larbre JP, Laurian Y, Molina V, Dirat G.

Haemophilia. 2008 Jul;14 Suppl 4:11-9. doi: 10.1111/j.1365-2516.2008.01734.x. Review.

PMID:
18494688
11.

Treatment of congenital afibrinogenemia in a premature neonate.

Toledano A, Lachassinne E, Roumegoux C, Laurian Y, Benabadji Z, Chiadmi F, Cisternino S, Schlatter J, Fontan JE.

Ann Pharmacother. 2008 Jul;42(7):1145-6. doi: 10.1345/aph.1L132. Epub 2008 Jun 17. No abstract available.

PMID:
18559953
12.

A natural variant with a point mutation resulting in a homozygous Arg to His substitution at position 388 in prothrombin.

d'Audigier C, Pasmant E, Bournier O, Laurian Y, Guillin MC, Bezeaud A.

Haematologica. 2008 May;93(5):799-800. doi: 10.3324/haematol.12520. No abstract available.

13.

Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies.

Calvez T, Laurian Y, Goudemand J.

J Thromb Haemost. 2008 Feb;6(2):390-2. Epub 2007 Nov 23. Review. No abstract available.

PMID:
18036187
14.
15.

Risk of inhibitors in haemophilia and the type of factor replacement.

Goudemand J, Laurian Y, Calvez T.

Curr Opin Hematol. 2006 Sep;13(5):316-22. Review.

PMID:
16888435
16.

Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for hemophilia A: results from a single institution.

Guillet B, Lambert T, d'Oiron R, Proulle V, Plantier JL, Rafowicz A, Peynet J, Costa JM, Bendelac L, Laurian Y, Lavergne JM.

Hum Mutat. 2006 Jul;27(7):676-85.

PMID:
16786531
17.

Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required.

Calvez T, Laurian Y.

Br J Haematol. 2006 Mar;132(6):798-800; author reply 800-1. No abstract available.

PMID:
16487187
18.

Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents.

Poon MC, Zotz R, Di Minno G, Abrams ZS, Knudsen JB, Laurian Y.

Semin Hematol. 2006 Jan;43(1 Suppl 1):S33-6. Review.

PMID:
16427383
19.

Red blood cell transfusion in patients with type 1 Glanzmann's thrombasthenia.

Laurian Y, Tisseron-Maury B, Bibi Triki T, Kaplan C, Gaudelus J.

J Thromb Haemost. 2005 Oct;3(10):2346-7. No abstract available.

PMID:
16194208
20.

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T; FVIII-LFB and Recombinant FVIII study groups.

Blood. 2006 Jan 1;107(1):46-51. Epub 2005 Sep 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk